β受体阻滞剂局部外用治疗婴幼儿血管瘤的meta分析

Meta-analysis onthe treatment of infant hemangioma with topical β-receptor blocker

目的探讨β受体阻滞剂局部外用对婴幼儿血管瘤的疗效及安全性的研究现状,为临床提供循证医学依据及参考。方法在中英文数据库中检索截至2014年6月的所有关于β受体阻滞剂局部外用治疗婴幼儿血管瘤的文献进行Meta分析。结果利用上述检索策略共检出76篇相关文献,最终纳入文献8篇。(1)β受体阻滞剂局部外用治疗组效果高于安慰剂生臣/观察组,差异有显著性(P<0.00001)。(2)β受体阻滞剂局部外用组疗效和口服普萘洛尔组疗效差异无显著性(P=0.41)。(3)β受体阻滞剂局部外用组全身不良反应少于口服普萘洛尔组,差异有显著性(P=0.002)。结论β受体阻滞剂局部外用疗效和口服普萘洛尔治疗婴幼儿血管瘤无显著差异,全身不艮反应相对更少。

Objective This study is aims to provide evidence for evidence-based medicine and reference in clinical through the recta-analysis of the effectiveness and safety of topical β- receptor blocker infant hemangioma therapy. Methods This recta-analysis included literatures were retrieved from all database of China and England by January 2014. Results There are 76 literatures and eight literature were included in this recta-analysis. ① The curative effect of topical β- receptor blocker group was better than placebo/observation group （ P 〈 0. 00001 ） ; ② The effect between topical β- receptor blocker and oral propranolol has no statistically significance difference （ P = 0. 41 ） ;③ The systematic side effect of topical β- receptor blocker are less than oral propranolol （ P = 0. 002 ）. Conclusions There are no difference between topical 13- receptor blocker and oral propranolol to treat infant hemangioma, and the systematic side effect of topicalβ- receptor blocker are less than oral propranolol.